Could your aspirin be failing you? trinidad study investigates
NCT ID NCT06228820
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed pilot study looked at whether some healthy adults are resistant to aspirin's blood-thinning effects. 48 participants took two different types of 81 mg aspirin for two weeks each, and their platelet function was measured. The goal was to understand how common aspirin resistance is and how well lab tests can detect it.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Aspirin (81 mg enteric-coated and 81 mg Vazalore aspirin)
- What this could lead to
- If successful, this could help identify why some people don't respond well to aspirin, potentially improving heart attack and stroke prevention strategies.
- What could go wrong
- This is a small pilot study with only 48 healthy participants, so results may not apply to the general population or those with medical conditions. The tests used are not perfectly accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
48 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 74 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. between 18 and 74 years of age, 2. healthy with no overt medical conditions, 3. not on any physician-prescribed medications or complementary/alternative therapies, Exclusion Criteria: 1. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding, 2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm, 3. clinical and/or hemodynamic instability, 4. within 1 month of placement of a bare metal stent, 5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed, 6. planned coronary revascularization, 7. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h, 8. use of an oral anticoagulation agent or international normalized ratio \>1.5, 9. body weight \<60 kg, 10. age \>75 years, 11. hemoglobin \<10 g/dL, 12. platelet count \<100×106/μL, 13. creatinine \>2 mg/dL, 14. hepatic enzymes \>2.5 times the upper limit of normal, 15. pregnancy and/or lactation, 16. the patient is on any other antithrombotic therapies such as ticagrelor, dabigatran, rivaroxaban and apixaban
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Platelet dysfunction due to drugs are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of the West Indies
Saint Augustine, North, 00000, Trinidad and Tobago